Related Experiment Video
Updated: Jul 17, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
A comparative assessment between Globorisk and WHO cardiovascular disease risk scores: a population-based study
Azizallah Dehghan1, Fatemeh Rezaei2, Dagfinn Aune3,4
1Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Insights
The World Health Organization (WHO) and Globorisk cardiovascular risk models show good agreement and very strong positive correlation. However, Globorisk classifies more individuals as high-risk, suggesting potential need for model adjustments.
Area of Science:
- Cardiovascular epidemiology
- Risk prediction modeling
- Public health
Background:
- Cardiovascular disease (CVD) risk prediction models like Globorisk and WHO are crucial for public health interventions.
- Existing models are often region-specific, necessitating validation in diverse populations.
- The Fasa cohort study provides a valuable dataset for evaluating CVD risk assessment tools.
Purpose of the Study:
- To assess the agreement and correlation between the WHO and Globorisk 10-year CVD risk prediction models.
- To compare laboratory-based and non-laboratory-based versions of these risk models.
- To evaluate the performance of these models in a specific population (Fasa cohort).
Main Methods:
- Utilized baseline data from 6796 individuals (aged 40-74) from the Fasa cohort study.
- Calculated CVD risk scores using WHO and Globorisk models (laboratory-based and non-laboratory-based).
- Employed kappa statistics for categorical agreement and Pearson correlation/Bland-Altman plots for continuous agreement.
Main Results:
- Substantial to almost perfect agreement was found between WHO and Globorisk models across risk categories (kappa values 0.73-0.82).
- Very strong positive correlations (r ≥ 0.95) were observed between laboratory-based and non-laboratory-based scores.
- Bland-Altman plots indicated systematic differences, with Globorisk identifying more high-risk individuals than WHO.
Conclusions:
- The WHO and Globorisk models demonstrate good agreement and strong correlation in this population.
- Systematic differences in risk stratification exist, particularly in higher-risk categories.
- Further validation and potential modification of risk category cut-points are recommended for these models in this population.
Abstract:
The Globorisk and WHO cardiovascular risk prediction models are country-specific and region-specific, respectively. The goal of this study was to assess the agreement and correlation between the WHO and Globorisk 10-year cardiovascular disease risk prediction models. The baseline data of 6796 individuals aged 40-74 years who participated in the Fasa cohort study without a history of cardiovascular disease or stroke at baseline were included. In the WHO and Globorisk models scores were calculated using age, sex, systolic blood pressure (SBP), current smoking, diabetes, and total cholesterol for laboratory-based risk and age, sex, SBP, current smoking, and body mass index (BMI) for non-laboratory-based risk (office-based or BMI-based). In Globorisk and WHO risk agreement across risk categories (low, moderate, and high) was examined using the kappa statistic. Also, Pearson correlation coefficients and scatter plots were used to assess the correlation between Globorisk and WHO models. Bland-Altman plots were presented for determination agreement between Globorisk and WHO risk scores in individual's level. In laboratory-based models, agreement across categories was substantial in the overall population (kappa values: 0.75) and also for females (kappa values: 0.74) and males (kappa values: 0.76), when evaluated separately. In non-laboratory-based models, agreement across categories was substantial for the whole population (kappa values: 0.78), and almost perfect for among males (kappa values: 0.82) and substantial for females (kappa values: 0.73). The results showed a very strong positive correlation (r ≥ 0.95) between WHO and Globorisk laboratory-based scores for the whole population, males, and females and also a very strong positive correlation (r > 0.95) between WHO and Globorisk non-laboratory-based scores for the whole population, males, and females. In the laboratory-based models, the limit of agreements was better in males (95%CI 2.1 to - 4.2%) than females (95%CI 4.3 to - 7.3%). Also, in the non-laboratory-based models, the limit of agreements was better in males (95%CI 2.9 to - 4.0%) than females (95%CI 3.2 to - 6.1%). There was a good agreement between both the laboratory-based and the non-laboratory-based WHO models and the Globorisk models. The correlation between two models was very strongly positive. However, in the Globorisk models, more people were in high-risk group than in the WHO models. The scatter plots and Bland-Altman plots showed systematic differences between the two scores that vary according to the level of risk. So, for these models may be necessary to modify the cut points of risk groups. The validity of these models must be determined for this population.
More Related Videos
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
06:57Author Spotlight: Advancing Cardiovascular Imaging - Introducing the Spatially Weighted Calcium Score for Early Disease Detection
Published on: September 22, 2023
Related Concept Videos
Relative Risk
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Hazard Ratio
For example, in a clinical trial...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Assessment of the Cardiovascular System II: Inspection
Head and Neck